Skip to NavigationSkip to content

EU green-lights Samsung Bioepis, Biogen's Remicade biosimilar Flixabi

Published on 31/05/16 at 08:44am

Samsung Bioepis and partner Biogen (Nasdaq: BIIB) said the European Commission has approved Flixabi, a biosimilar version of Johnson & Johnson (NYSE: JNJ) and Merck & Co's (NYSE: MRK) Remicade (infliximab).  

Flixabi is indicated as a treatment for rheumatoid arthritis (RA), Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and psoriasis.

Alpna Seth, global head of the biosimilars business unit at Biogen said: “The approval of Flixabi marks a major step forward for both Samsung Bioepis and Biogen. It expands our anti-TNF portfolio and furthers Biogen’s commitment to commercializing biosimilars of advanced biologics, while expanding cost-effective treatment options for patients living with chronic inflammatory conditions such as Crohn’s disease and ulcerative colitis.”

Flixabi will be the second anti-TNF biosimilar to be manufactured and commercialized by Biogen in the EU. Earlier this year, Samsung Bioepis received approval for Benepali (etanercept), a biosimilar copy of Amgen’s (Nasdaq: AMGN) Enbrel.

At an estimated $10 billion a year, anti-TNF therapies are among the EU’s largest drug expenditures, the companies said in a joint statement.

Anjali Shukla

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches